Prioritisation of treatment with direct acting oral anti-HCV drugs (DAA’s) in hepatitis C patients

Leading partner organisation: REGION HOVEDSTADEN/Centre of Excellence for Health, Immunity and Infections (CHIP) (Denmark)

Hepatitis C (HCV), in combination with excessive alcohol consumption, is a major cause of excess morbidity and mortality, especially in the Eastern region of Europe. With the availability of direct acting oral anti-HCV drugs (DAA) and rapidly dropping prices per patient, eradication of HCV appears possible. However, due to lack of access, insufficient medical services and lack of diagnosis, it is not feasible to provide treatment for all infected at the same time, therefore it compelling to identify prioritisation criteria for treatment initiation, especially for the public health and medical communities in Russia and other Eastern European countries, where the HCV-infected population is around 14 million people.

By preliminary comparing the Georgia HCV eradication programme with Western European programmes, CARE proposes to derive a strategy for direct acting antivirals DAA treatment implementation in Russia and other Eastern European countries.

Heading 1

Heading 1

Heading 1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.

Subscribe to the CARE newsletter

Francesca Incardona